A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 339-343

  Masson Lecomte, Alexandra ^a,g   Guy, Laurent ^b   Pedron, Philippe ^c   Bruyere, Franck ^d   Rouprêt, Morgan ^e,f   Nsabimbona, Bonaventure ^b   Dahan, Mickael ^c   Hoffman, Patrice ^c   Salomon, Laurent ^a   Vordos, Dimitri ^a   Hoznek, Andras ^a   Le Corvoisier, Philippe ^a   Morel, Pierrick ^a   Abbou, Claude ^a   de la Taille, Alexandre ^a,g  

^a HENRI MONDOR HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c Department of Urology   (France)

^d CHU BRETONNEAU   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Castration resistant prostate cancer; GnRH antagonist; PSA; Testosterone

Indexed keywords

EID: 84876422757     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0841-1     Document Type: Review

References (8)

1. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175(1): 27-34. doi: 10. 1016/S0022-5347(05)00034-0.
2. van Poppel H (2010) Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2: 39-52.
3. de la Rosette J, Davis R 3rd, Frankel D, Kold Olesen T (2011) Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract 65(5): 559-566. doi: 10. 1111/j. 1742-1241. 2011. 02637. x.
4. Raddin RS, Walko CM, Whang YE (2011) Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Anticancer Drugs 22(3): 299-302.
5. Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N (2011) Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 185(3): 848-854. doi: 10. 1016/j. juro. 2010. 10. 055.
6. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE (2011) A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186(3): 889-897. doi: 10. 1016/j. juro. 2011. 04. 083.
7. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB (1999) Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91(3): 244-251.
8. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363(17): 1621-1630. doi: 10. 1056/NEJMoa1001283.